References
- Bell W.R., Braine H.G., Ness P.M., et al. Improved survival in thrombotic throbmocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N. Engl. J. Med. 1991; 398–403
- Ruggenenti P., Remuzzi G. Thrombotic thrombocy-topenic purpura and related disorders. Hematol. Oncol. Clin. North. Am. 1990; 219–242
- Botti A.C., Hyde P., DiPillo F. Thrombotic thrombo-cytopenic purpura in a patient who subsequently developed the acquired immunodeficiency syndrome. Ann. Intern. Med. 1988; 242–243
- Moake J.L., Rudy C.D., Troll J.H., et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N. Engl. J. Med. 1982; 1432–1435
- Kasper C.K. Treatment of factor VIII inhibitors. Prog. Hemost. Thromb. 1989; 57–86
- Doane L.L., Ratain M.J., Golomb H.M. Hairy cell leukemia. Hematol. Oncol. Clin. North. Am. 1992; 489–502
- Folkman J. Successful treatment of an angiogenic disease. N. Engl. J. Med. 1989; 1211–1212
- Ezekowitz R.A., Mulliken J.B., Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 1992; 1456–1463
- White C.W., Sondheimer H.M., Crouch E.C., et al. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N. Engl. J. Med. 1989; 1197–1200
- Dvorak H.F., Gresser I. Microvascular injury in the pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J. Natl. Cancer Inst. 1989; 497–502
- Jandl J. Disorders of coagulation. Blood. Textbook of Hematology1st ed., J. Jandl. Little Brown, Boston 1987; 785–796
- Naumovski L., Pillsbury H.E. Treatment of thrombotic thrombocytopenic purpura with supernatant. Am. J. Hematol. 1991; 250–251
- Lottenberg R., Kentro T.B., Kitchens C.S. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch. Intern. Med. 1987; 1077–1081
- Komminoth A., Dufour P., Bergerat J.P. Hairy cell leukemia and factor VIII inhibitor: a case report. Nouv. Rev. Fr. Hematol. 1992; 269–211
- Silvestri F., Virgolini L., Mazzolini A., et al. Development of autoimmune thyroid diseases during long-term treatment of hemato-logical malginancies with alpha-interferons. Hematologica 1994; 367–370
- D'Hondt L., Delannoy A., Docquier C. Hypothyroidism and arthritis during interferon therapy. Clin. Rheum. Dis. 1993; 415–417
- Chung Y.H., Shong Y.K. Development of thyroid au-toimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis. Am. J. Gastroenterol. 1993; 244–247
- Ronnblom L.E., Aim G.V., Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during in-terferon-alpha treatment. Ada. Oncol. 1991; 537–540
- Weber P., Wiedmann K.H., Klein R., et al. Induction of autoimmune phenomena in patients with chronic hepatitis B treated with gamma-interferon. J. Hepatoi 1994; 321–328
- Lian E. Pathogenesis of thrombotic thrombocytopenic purpura. Semin. Hematol. 1987; 82–100
- Moake J.L., Byrnes J.J., Troll J.H., et al. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1985; 1232–1236
- Byrnes J.J., Moake J.L., Klug P., et al. Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am. J. Hematol. 1990; 169–174